Therapy with clopidogrel or rivaroxaban has equivalent impacts on recurrence of thromboembolism and survival in cats following cardiogenic thromboembolism: the SUPERCAT study
In cats that have recovered from cardiogenic ATE, either rivaroxaban or clopidogrel may be used for single-agent thromboprophylaxis to delay ATE recurrence.
Authors
- John E. Rush (ORCID: https://orcid.org/0000-0002-8277-8996)
- Amanda Erickson Coleman (ORCID: https://orcid.org/0000-0001-5476-5963)
- Marjory B. Brooks (ORCID: https://orcid.org/0000-0001-5489-9013)
- Marc S. Kraus (ORCID: https://orcid.org/0000-0002-8715-5376)
- Benjamin M. Brainard (ORCID: https://orcid.org/0000-0003-4299-2936)
- Anne Kurosawa
- Daniel F. Hogan
Institutions
- Tufts University (US)
- University of London (GB)
- Royal Veterinary College (GB)
- University of Georgia (US)
- Cornell University (US)
- Purdue University West Lafayette (US)
- New York State College of Veterinary Medicine (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of the American Veterinary Medical Association
- Published
- 2024-12-18
- DOI
- https://doi.org/10.2460/javma.24.09.0584
- Citations
- 6
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.30
Funders
- Bristol-Myers Squibb
- Sanofi
- Zoetis